State AL
Clinical Trials in Alabama
Alabama is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in Alabama and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.
Right now ClinicalMetric tracks 158 actively recruiting studies with Alabama sites out of 158 registered in total. The busiest research areas in Alabama are Obesity, Ovarian Cancer, Prostate Cancer. Leading sponsors running trials in the state include University of Alabama at Birmingham, AstraZeneca, Pfizer. By stage, Alabama trials break down as Phase 1 (20), Phase 2 (43), Phase 3 (47), Phase 4 (8).
All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.
Top Conditions in Alabama
Frequently Asked Questions — Clinical Trials in Alabama
How many clinical trials are currently recruiting in Alabama?
ClinicalMetric currently tracks 158 actively recruiting clinical trials with at least one location in Alabama. The total number of registered studies—including active but not currently enrolling trials—is 158. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Alabama?
Alabama hosts clinical trials across a broad range of medical conditions, including Obesity, Ovarian Cancer, Prostate Cancer, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Alabama serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Alabama?
To join a clinical trial in Alabama, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Alabama maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Alabama
NCT06315309 Phase 2
Recruiting
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem...
Condition
GVHD,Acute
Enrollment
29 pts
Location
United States
Sponsor
University of Alabama at Birmi
NCT06419374 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With...
Condition
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Enrollment
1,800 pts
Location
United States, Argentina, Australia
Sponsor
Hoffmann-La Roche
NCT06797518 Phase 2
Recruiting
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kid...
Condition
Glomerulonephritis, IGA
Enrollment
20 pts
Location
United States, Argentina, Israel
Sponsor
Novartis Pharmaceuticals
NCT07523113 N/A
Recruiting
ME/CFS Brain Fog: Cognitive Rehabilitation Trial
Condition
ME/CFS
Enrollment
30 pts
Location
United States
Sponsor
University of Alabama at Birmi
NCT07226232 Phase 3
Recruiting
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
Condition
Major Depression
Enrollment
240 pts
Location
United States
Sponsor
VA Office of Research and Deve
NCT05850234 Phase 1, Phase 2
Recruiting
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Condition
Relapsed/Refractory Multiple Myeloma
Enrollment
232 pts
Location
United States
Sponsor
AstraZeneca
NCT06456593 Phase 2
Recruiting
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active...
Condition
Moderately to Severely Active Crohn Disease
Enrollment
212 pts
Location
United States, Belgium, Czechia
Sponsor
Abivax S.A.
NCT05919511 N/A
Recruiting
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
Condition
cGVHD
Enrollment
1,500 pts
Location
United States
Sponsor
Incyte Corporation
NCT06424288 Phase 3
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps Peop...
Condition
Heart Failure
Enrollment
6,712 pts
Location
United States, Argentina, Australia
Sponsor
Boehringer Ingelheim
NCT07355296 Phase 2
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents...
Condition
Proteinuric Kidney Diseases
Enrollment
132 pts
Location
United States, Argentina, Australia
Sponsor
Boehringer Ingelheim
NCT06855654 N/A
Recruiting
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
Condition
Breast Cancer
Enrollment
120 pts
Location
United States
Sponsor
UNC Lineberger Comprehensive C
NCT07281079 Phase 3
Recruiting
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Condition
Phelan-McDermid Syndrome
Enrollment
160 pts
Location
United States, Canada
Sponsor
Neuren Pharmaceuticals Limited
NCT07361510 Phase 3
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participan...
Condition
Non-Small Cell Lung Cancer (NSCLC)
Enrollment
750 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT07028749 Phase 2
Recruiting
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
Condition
Hypertriglyceridemia
Enrollment
316 pts
Location
United States, Australia, Canada
Sponsor
Marea Therapeutics
NCT07775300 Phase 3
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive D...
Condition
Depressive Disorder, Major
Enrollment
1,000 pts
Location
United States, Australia, Brazil
Sponsor
Eli Lilly and Company
NCT06207032 N/A
Recruiting
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Condition
Cancer
Enrollment
500 pts
Location
United States, Puerto Rico
Sponsor
Tempus AI
NCT07223593 Phase 3
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disea...
Condition
Peripheral Arterial Disease
Enrollment
1,205 pts
Location
United States, Argentina, Australia
Sponsor
Eli Lilly and Company
NCT07318558 Phase 3
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Can...
Condition
Ovarian Neoplasms
Enrollment
900 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT00736749 N/A
Recruiting
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Gro...
Condition
Hematopoietic Cell Transplantation Recipient
Enrollment
25,000 pts
Location
United States, Puerto Rico
Sponsor
Children's Oncology Group
NCT07137273 N/A
Recruiting
Optimizing Dimensions of Reinforcement
Condition
Intellectual Disabilities (F70-F79)
Enrollment
30 pts
Location
United States
Sponsor
Auburn University
NCT06335524 N/A
Recruiting
Infant-Maternal Partnership and Cognitive Training Study for Preterm Infants
Condition
Child Development
Enrollment
188 pts
Location
United States
Sponsor
University of Alabama at Birmi
NCT06810505 Phase 3
Recruiting
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease...
Condition
Chronic Migraine
Enrollment
420 pts
Location
United States, Canada, Denmark
Sponsor
AbbVie
NCT05006482 Phase 3
Recruiting
Geriatric Evaluation and Management With Survivorship Health Education for Older...
Condition
Lymphoma
Enrollment
668 pts
Location
United States
Sponsor
University of Rochester
NCT05918861 Phase 3
Recruiting
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Rece...
Condition
Acute Coronary Syndrome
Enrollment
2,000 pts
Location
United States, Canada, Puerto Rico
Sponsor
DalCor Pharmaceuticals
NCT03072927 N/A
Recruiting
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Condition
Lumbar Spinal Stenosis
Enrollment
8,000 pts
Location
United States
Sponsor
Stryker Instruments
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology